NCT00338598View on ClinicalTrials.gov

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
AlcoholismSchizophrenia
Interventions
DRUG

Glycine

Glycine, 0.8 gr per kg given in two daily doses

DRUG

placebo

Trial Locations (1)

06516

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Yale University

OTHER

NCT00338598 - Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism | Biotech Hunter | Biotech Hunter